Immunovia Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
Individual Insiders | 17,549,278 | 6.7% |
Institutions | 42,322,579 | 16.2% |
General Public | 202,037,006 | 77.1% |
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 478.3%.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
30,331,615 | SEK 10.9m | 53.9% | 0.01% | |||
5,981,000 | SEK 2.1m | 0% | no data | |||
2,989,038 | SEK 1.1m | 0% | 0.02% | |||
2,023,450 | SEK 726.4k | 0% | no data | |||
1,909,900 | SEK 685.7k | 0% | no data | |||
1,692,555 | SEK 607.6k | 0% | no data | |||
1,615,000 | SEK 579.8k | 0% | no data | |||
1,583,668 | SEK 568.5k | 0% | 100.0% | |||
1,470,588 | SEK 527.9k | 0% | 100.0% | |||
1,358,834 | SEK 487.8k | 0% | no data | |||
1,319,706 | SEK 473.8k | 0% | no data | |||
1,303,968 | SEK 468.1k | 0% | no data | |||
848,950 | SEK 304.8k | 0% | no data | |||
848,907 | SEK 304.8k | 0% | no data | |||
748,525 | SEK 268.7k | 0% | no data | |||
692,027 | SEK 248.4k | 0% | 0.02% | |||
660,884 | SEK 237.3k | 0% | no data | |||
495,038 | SEK 177.7k | 0% | no data | |||
481,387 | SEK 172.8k | 0% | no data | |||
473,678 | SEK 170.1k | 53.9% | no data | |||
468,500 | SEK 168.2k | 0% | no data | |||
423,139 | SEK 151.9k | 0% | no data | |||
350,000 | SEK 125.6k | 0% | no data | |||
200,000 | SEK 71.8k | 0% | no data | |||
131,017 | SEK 47.0k | 0% | no data |
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/13 02:38 |
End of Day Share Price | 2025/03/13 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunovia AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Herman Kuntscher | Carlsquare AB |
Lars Hevreng | Danske Bank |
Juan Pedro Rodríguez Serrate | Edison Investment Research |